Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Basis Of Presentation [Line Items]
Net loss	$ (6,485)	$ (5,849)
Proceeds from the sale of common stock and pre-funded warrants, net of fees	2,784	8,503
Working capital	3,600		$ 5,200
Cash and cash equivalents	6,393		6,566
Accounts receivable, net	$ 5,687		$ 5,483
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001
Principal Payment On Loan	$ 165	0
Proceeds from disposal of property, plant, and equipment	197	$ 0
February 2024 Public Offering [Member]
Basis Of Presentation [Line Items]
Net loss	(6,500)
Proceeds from the sale of common stock and pre-funded warrants, net of fees	5,800
Principal Payment On Loan	200
Proceeds from disposal of property, plant, and equipment	$ 200
Biolase Stockholders [Member]
Basis Of Presentation [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001
Reverse Stock Split	a reverse stock split of BIOLASE common stock, par value $0.001 per share (the “common stock”), at a ratio between one-for-two (1:2) and one-for-one hundred (1:100). Immediately after the special meeting, BIOLASE's board of directors (the "Board") approved a one-for-one hundred (1:100) reverse stock split of the outstanding shares of the common stock (the “2023 Reverse Stock Split”).